Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Indonesia Rejects Complaints About New Drug Production Rule

This article was originally published in PharmAsia News

Executive Summary

Indonesia's health minister dismissed complaints about new rules requiring foreign drug makers to have a local production facility before they can sell in the country. Minister Siti Fadilah Supari said the intent of the new rules was to force the companies to invest in the country instead of taking advantage of its potential for sales. Thirteen multinational pharmaceuticals are affected by the rule since they market products in the country, but do not have a production facility in Indonesia. A U.S. business group complained about the rule that requires foreign pharmas to establish production facilities in Indonesia within two years or stop selling their products in the $2 billion-a-year market. Critics of the rule say it could lead to a lack of some life-saving drugs in Indonesia. (Click here for more

You may also be interested in...



Indonesia Decree Requiring Foreign Drug Makers To Build Local Plants “Disastrous”

PERTH, Australia - A decree issued by Indonesia's health minister earlier this month requiring foreign drug manufacturers to build manufacturing plants in the country, or leave, would be disastrous to the industry, an industry leader said

California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits

The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.

Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer

Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025.  It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.

Latest Headlines
See All
UsernamePublicRestriction

Register

SC067351

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel